GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (STU:5GZ) » Definitions » ROCE %

Waverley Pharma (STU:5GZ) ROCE % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Waverley Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Waverley Pharma's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.


Waverley Pharma ROCE % Historical Data

The historical data trend for Waverley Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma ROCE % Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial -42.52 -27.79 -42.27 -44.41 -

Waverley Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.22 -967.29 - - -

Waverley Pharma ROCE % Calculation

Waverley Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.843/( ( (1.867 - 1.109) + (0.651 - 1.428) )/ 2 )
=-0.843/( (0.758+-0.777)/ 2 )
=-0.843/-0.0095
=8,873.68 %

Waverley Pharma's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=-2.052/( ( (0.57 - 1.521) + (1.185 - 2.385) )/ 2 )
=-2.052/( ( -0.951 + -1.2 )/ 2 )
=-2.052/-1.0755
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (STU:5GZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Waverley Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.

Waverley Pharma Headlines

No Headlines